Skip to main content
Log in

MFH of Bone and Osteosarcoma Show Similar Survival and Chemosensitivity

  • Clinical Research
  • Published:
Clinical Orthopaedics and Related Research®

Abstract

Background

Patients with malignant fibrous histiocytoma of bone (MFH-B) and osteosarcoma reportedly have comparable survival rates, despite the lesser chemosensitivity of patients with MFH-B compared with those with osteosarcoma.

Questions/purposes

We therefore asked (1) whether there is a difference in the initial tumor volume, histologic response, and survival between cohorts with MFH-B and osteosarcoma, and (2) whether histologic responses and survival rates differed between two groups even after matching for volume and age.

Patients and Methods

We retrospectively compared 27 patients with Stage IIB MFH-B with 389 patients with localized osteosarcoma for initial tumor volume, age, histologic response, and survival. We compared histologic response and survival between 27 patients with MFH-B and 54 patients with osteosarcoma matched for tumor volume and age.

Results

MFH-B occurred more frequently in older patients and they presented with a smaller mean tumor volume and more frequent osteolytic pattern when compared with patients with osteosarcoma. The 5-year metastasis-free survival rates of the MFH-B and osteosarcoma groups were similar: 61.2% ± 9.7% and 61.3% ± 2.5%, respectively. We observed similar proportions of good responders to chemotherapy in the two groups, and the 5-year metastasis-free survival rates were 61.2% ± 9.7% and 70.4% ± 6.2%, respectively.

Conclusions

Patients with MFH-B and osteosarcoma have similar survival rates and histologic responses to chemotherapy. Although MFH-B and osteosarcoma differ in clinical presentation, their response pattern to contemporary therapy is similar.

Level of Evidence

Level III, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bacci G, Ferrari S, Bertoni F, Mercuri M, Forni C, Sottili S, Gasbarrini A, Tienghi A, Cesari M, Campanacci M. Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen. J Chemother. 1997;9:293–299.

    CAS  PubMed  Google Scholar 

  2. Bacci G, Picci P, Mercuri M, Bertoni F, Ferrari S. Neoadjuvant chemotherapy for high grade malignant fibrous histiocytoma of bone. Clin Orthop Relat Res. 1998;346:178–189.

    Article  PubMed  Google Scholar 

  3. Bielack SS, Schroeders A, Fuchs N, Bacci G, Bauer HC, Mapeli S, Tomeno B, Winkler K. Malignant fibrous histiocytoma of bone: a retrospective EMSOS study of 125 cases. European Musculo-Skeletal Oncology Society. Acta Orthop Scand. 1999;70:353–360.

    Article  CAS  PubMed  Google Scholar 

  4. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848–858.

    CAS  PubMed  Google Scholar 

  5. Bramwell VH, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, Taminau AH, Cannon SR, Malcolm AJ, Hogendoorn PC, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol. 1999;17:3260–3269.

    CAS  PubMed  Google Scholar 

  6. Capanna R, Bertoni F, Bacchini P, Bacci G, Guerra A, Campanacci M. Malignant fibrous histiocytoma of bone: the experience at the Rizzoli Institute. Report of 90 cases. Cancer. 1984;54:177–187.

    Article  CAS  PubMed  Google Scholar 

  7. Dahlin DC, Unni KK, Matsuno T. Malignant (fibrous) histiocytoma of bone: fact or fancy? Cancer. 1977;39:1508–1516.

    Article  CAS  PubMed  Google Scholar 

  8. den Heeten GJ, Schraffordt Koops H, Kamps WA, Oosterhuis JW, Sleijfer DT, Oldhoff J. Treatment of malignant fibrous histiocytoma of bone: a plea for primary chemotherapy. Cancer. 1985;56:37–40.

    Article  Google Scholar 

  9. deSantos LA, Edeiken B. Purely lytic osteosarcoma. Skeletal Radiol. 1982;9:1–7.

    Article  CAS  PubMed  Google Scholar 

  10. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–120.

    PubMed  Google Scholar 

  11. Ham SJ, Hoekstra HJ, van der Graaf WT, Kamps WA, Molenaar WM, Schraffordt Koops H. The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone. J Clin Oncol. 1996;14:490–496.

    CAS  PubMed  Google Scholar 

  12. Huvos AG, Heilweil M, Bretsky SS. The pathology of malignant fibrous histiocytoma of bone: a study of 130 patients. Am J Surg Pathol. 1985;9:853–871.

    Article  CAS  PubMed  Google Scholar 

  13. Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Shin DS, Jeon DG. Prognostic effect of inadvertent curettage without treatment delay in osteosarcoma. J Surg Oncol. 2009;100:484–487.

    Article  PubMed  Google Scholar 

  14. Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Shin DS, Jeon DG. Prognostic effects of doctor-associated diagnostic delays in osteosarcoma. Arch Orthop Trauma Surg. 2009;129:1421–1425.

    Article  PubMed  Google Scholar 

  15. Link TM, Haeussler MD, Poppek S, Woertler K, Blasius S, Lindner N, Rummeny EJ. Malignant fibrous histiocytoma of bone: conventional X-ray and MR imaging features. Skeletal Radiol. 1998;27:552–558.

    Article  CAS  PubMed  Google Scholar 

  16. Murphey MD, Gross TM, Rosenthal HG (1994) From the archives of the AFIP. Musculoskeletal malignant fibrous histiocytoma: radiologic-pathologic correlation. Radiographics 14:807–826; quiz 827–828.

    CAS  PubMed  Google Scholar 

  17. Naka T, Fukuda T, Shinohara N, Iwamoto Y, Sugioka Y, Tsuneyoshi M. Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years: a clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma. Cancer. 1995;76:972–984.

    Article  CAS  PubMed  Google Scholar 

  18. Nishida J, Sim FH, Wenger DE, Unni KK. Malignant fibrous histiocytoma of bone: a clinicopathologic study of 81 patients. Cancer. 1997;79:482–493.

    Article  CAS  PubMed  Google Scholar 

  19. Picci P, Bacci G, Ferrari S, Mercuri M. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Ann Oncol. 1997;8:1107–1115.

    Article  CAS  PubMed  Google Scholar 

  20. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–1230.

    Article  CAS  PubMed  Google Scholar 

  21. Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A, Cacavio A, Groshen S. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(suppl):55–67.

    Article  PubMed  Google Scholar 

  22. Shin KH, Moon SH, Suh JS, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res. 2000;376:200–208.

    Article  PubMed  Google Scholar 

  23. Spanier SS, Enneking WF, Enriquez P. Primary malignant fibrous histiocytoma of bone. Cancer. 1975;36:2084–2098.

    Article  CAS  PubMed  Google Scholar 

  24. Yokoyama R, Tsuneyoshi M, Enjoji M, Shinohara N, Masuda S. Prognostic factors of malignant fibrous histiocytoma of bone: a clinical and histopathologic analysis of 34 cases. Cancer. 1993;72:1902–1908.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank J.S. Koh, MD, M.S. Kim, MD, and Yijung Seo, RN for assistance with pathologic reviews and data collection.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dae-Geun Jeon MD.

Additional information

The authors certify that they have no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might constitute a conflict of interest in connection with the submitted article.

The authors certify that their institution approved the human protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research.

About this article

Cite this article

Jeon, DG., Song, W.S., Kong, CB. et al. MFH of Bone and Osteosarcoma Show Similar Survival and Chemosensitivity. Clin Orthop Relat Res 469, 584–590 (2011). https://doi.org/10.1007/s11999-010-1428-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11999-010-1428-z

Keywords

Navigation